Industrial co-operation
A greener alternative for aviation fuel
Air travel with no carbon footprint – PSI and the Metafuels AG develop a new technology to produce sustainable aviation fuel.
High-tech company VDL ETG: PSI’s new neighbour
The Dutch company VDL ETG has signed a rental agreement with Park Innovaare.
Swiss PIC to support Swiss photonics industry
The technology transfer centre Swiss PIC will be located in the Park Innovaare.
10 Years anniversary of Excelsus
The PSI spin-off "Excelsus Structural Solutions" performs measurements at the SLS on behalf of customers.
“If you’re in a certain position, you should step forward”
Kirsten Moselund heads the new Laboratory for Nano and Quantum Technologies. In this interview she discusses quantum research at PSI and how nanophotonics can assist with this.
Novel X-ray lens facilitates glimpse into the nanoworld
PSI develops a revolutionary achromatic lens for X-rays.
A lively enterprise zone close by
Park Innovaare located next to PSI is growing, further pursuing its mission to help cutting-edge Swiss research transition to concrete applications and profitable companies.
New catalysts for pharmaceutical companies
In partnership with Roche, PSI scientists are developing new, potentially more efficient catalysts for manufacturing active substances for drug therapies.
Getting maximum energy out of biomass
Researchers at the Paul Scherrer Institute PSI start operation of a revolutionary pilot plant for production of synthetic biogas.
The link between theory and experiment
Without fundamental constants there is no physics.
How catalysts age
Catalysts used in industry change their material structure over the years. Using a new method, PSI researchers have now studied this on the nanoscale.
Patents as trump cards
John Millard is head of Technology Transfer at PSI. Intellectual property also falls within this area. In an interview, he tells how PSI protects its knowledge with patents and, thanks to its patents, further strengthens collaboration with industry and other research institutions.
Research with a patent
At PSI, researchers develop innovative technologies, new biological agents, and more precise measuring instruments. Through this work they not only advance science, but also boost the Swiss economy. The best ideas are protected by patents and make PSI a sought-after partner for industry.
Swiss STIX X-ray telescope sets off for the sun
On 10 February, the ESA mission Solar Orbiter is scheduled to start. The Swiss X-ray telescope STIX will be launching too – with detectors developed at PSI.
Observing solid-state batteries during deformation
PSI researchers have observed mechanical processes in solid-state batteries with unprecedented precision. Using X-ray tomography at the Swiss Light Source SLS, they discovered how fissures inside the batteries propagate. These insights can help to make batteries for electric cars or smartphones safer and more efficient.
PSI imaging helps with rocket launches
PSI researchers are helping the European space program: Their neutron imaging serves to ensure the quality of critical components for rocket launches.
Watching electrons and switching bits on
Electronics should get smaller, faster, and above all more energy-efficient. These themes are also present in several research groups at PSI. From incremental improvements to complete rethinking – who is currently working on what?
On the go at 200 kilometres per hour
Fabia Gozzo is no woman for the comfort zone. First she made a beamline at the Swiss Light Source SLS of the Paul Scherrer Institute PSI into one of the world's leading facilities. Today she is making her knowledge available to industry with her spin-off.
Licence agreement with Swiss pharma firm for development of a cancer drug
A radioactive agent, developed at the Paul Scherrer Institute PSI to fight an especially malignant form of thyroid cancer, has the potential to become a blockbuster drug. Due to its structure, it might also be able to dock onto cells of other tumours and destroy them with its radiation. The Lausanne-based biopharmaceutical company Debiopharm wants to further develop the PSI agent to the point where it is approved as a drug. Debiopharm and PSI have now created the contractual basis for this.
From researcher to entrepreneur
Towards new shores: At the Paul Scherrer Institute PSI, enterprising researchers are venturing into the unknown. They're leaving their safe haven to become successful entrepreneurs. The journey from PSI to one's own spin-off takes courage. To keep the voyage from getting too stormy, PSI supports its business founders as they navigate through rough waters, and maintains these connections over many years.
